The European Medicines Agency (EMA) has recommended the approval of Imdylltra (tarlatamab) in the EU. The drug is intended for the monotherapy of adult patients with an extensive stage of small cell lung cancer, in whom the disease has relapsed. Imdylltra represents a new treatment option for this group of patients. The approval of the drug by the EMA is an important step towards its availability for patients in Europe. Advanced stage small cell lung cancer is an aggressive disease with limited treatment options after recurrence. Tarlatamab is an immunotherapy that targets specific cancer cells.